Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the sale, the general counsel owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Maravai LifeSciences Stock Down 0.4%
MRVI stock traded down $0.02 during midday trading on Wednesday, reaching $5.08. The company had a trading volume of 2,704,757 shares, compared to its average volume of 1,896,170. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.99 and a 1 year high of $5.30. The company has a current ratio of 5.91, a quick ratio of 4.96 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $1.31 billion, a P/E ratio of -7.15 and a beta of 0.72. The company has a 50 day moving average of $3.92 and a two-hundred day moving average of $3.61.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The company had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. On average, equities research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Research Report on MRVI
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in Maravai LifeSciences by 49.0% in the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after acquiring an additional 3,209 shares during the period. Sprott Inc. bought a new position in Maravai LifeSciences in the 3rd quarter worth $29,000. Virtu Financial LLC bought a new position in Maravai LifeSciences in the 4th quarter worth $34,000. Insigneo Advisory Services LLC bought a new position in Maravai LifeSciences in the 4th quarter worth $34,000. Finally, Quantessence Capital LLC bought a new position in Maravai LifeSciences in the 3rd quarter worth $31,000. Institutional investors own 50.25% of the company’s stock.
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.
Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.
Featured Stories
- Five stocks we like better than Maravai LifeSciences
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
